**Suplementary Table 1: Baseline characteristics of suspected RH**

|  |  |
| --- | --- |
| Anthropometric measures | Patients (N=60) |
| Age, years (SD) | 63.73 (9.77) |
| Male, n (%) | 41 (68.3) |
| Body mass index, kg/m2 (SD) | 30.86 (4.22) |
| Waist circumference, cm (SD) | 107.38 (10.23) |
| Office systolic BP, mmHg (SD) | 154.27 (14.41) |
| Office diastolic BP, mmHg (SD) | 84.38 (13.67) |
| Cardiovascular risk factors |
| Family history of early CVD, n (%) | 6 (10) |
| Previous cardiovascular event, n (%) | 8 (13.3) |
| Current smokers, n (%) | 12 (20) |
| Diabetes, n (%) | 30 (50) |
| Dyslipidemia, n (%) | 39 (65) |
| Chronic kidney disease, n (%) | 10 (16.7) |
| Obesity, n (%) | 35 (58.3) |
| Target organ damage |
| Left ventricular hypertrophy (ECG), n (%) | 18 (30) |
| Left ventricular hypertrophy (echo), n (%) | 23 (38.3) |
| Glomerular filtration rate <60 ml/min, n (%)UACR, mg/gr, n(%) | 11 (18.3)31(54.4) |
| Antihypertensive treatment |
| Number of antihypertensive drugs, n (SD) | 3.63 (0.55) |
| Fixed-dose combination, n (%) | 36 (60) |
| Combination of 3 drugs, n (%) | 24 (40) |
| Combination of more than 3 drugs, n (%)  | 36 (60) |
| ACE inhibitors (%) | 30 |
| ARB (%) | 70 |
| Calcium channel blockers (%) | 83.3 |
| Diuretics (%) | 90 |
| Beta-adrenergic antagonists (%) | 51.7 |
| Alpha-adrenergic antagonists (%) | 33.3 |
| Aldosterone receptor antagonists (%) | 6.7 |
| Values are mean (SD) except for qualitative variables, expressed as n (%). BP: blood pressure; CVD: cardiovascular disease; ECG: electrocardiogram; UACR: urine albumin-to-creatinine ratio. |